Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization

This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.

Bibliographische Detailangaben

Veröffentlicht in:	JAMA network open 2022-08, Vol.5 (8), p.e2228997-e2228997
Hauptverfasser:	Anderson, Timothy S., O’Donoghue, Ashley, Mechanic, Oren, Dechen, Tenzin, Stevens, Jennifer
Format:	Artikel
Sprache:	eng
Schlagworte:	Health Policy Immunotherapy Monoclonal antibodies Online Only Research Letter Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!